Breaking Down Creative Medical Technology Holdings, Inc. (CELZ) Financial Health: Key Insights for Investors

Are you keeping a close watch on Creative Medical Technology Holdings, Inc. (CELZ) and trying to understand its financial standing? As of December 31, 2024, this commercial-stage biotechnology company, with a market cap of $5.7 million, reported a loss of $5.5 million for the fiscal year. But is this a cause for concern, or an opportunity? Analysts predict a final loss in 2026, followed by a profit of $18 million in 2027. Can CELZ achieve the anticipated 60% average annual growth rate needed to reach profitability in just a couple of years, or will the road to profitability be longer? Dive in to explore the key insights that can help you make informed decisions about CELZ.

Creative Medical Technology Holdings, Inc. (CELZ) Revenue Analysis

Analyzing Creative Medical Technology Holdings, Inc. (CELZ) requires a close look at its revenue streams to understand its financial health. Revenue streams can be influenced by product offerings, service delivery, and geographic markets.

Here's a breakdown of what to consider:

• Primary Revenue Sources: Identify whether the company's revenue comes primarily from products, services, or a combination of both.
• Year-over-Year Revenue Growth: Examine the historical revenue trends to determine the percentage increase or decrease in revenue each year.
• Business Segment Contribution: Evaluate how different business segments contribute to the overall revenue.
• Significant Changes: Note any significant changes in revenue streams, such as new product launches or shifts in market focus.

As of the latest information available, Creative Medical Technology Holdings, Inc. (CELZ) reported total revenue of $200,000 for the year ended September 30, 2024. This represents a decrease of $48,744, or 19.6%, compared to the year ended September 30, 2023, when total revenue was $248,744. The decrease was primarily due to decreased sales of StemSpine® and related products.

Here's a summary of the revenue streams and changes:

Understanding the trends in these revenue streams is essential for investors. For instance, the decrease in StemSpine® sales suggests potential challenges in that product line, which could impact future revenue projections. Monitoring these changes helps in assessing the company’s financial stability and growth potential.

Further insights into Creative Medical Technology Holdings, Inc. (CELZ)’s financial health can be found at: Breaking Down Creative Medical Technology Holdings, Inc. (CELZ) Financial Health: Key Insights for Investors

Creative Medical Technology Holdings, Inc. (CELZ) Profitability Metrics

Assessing the profitability of Creative Medical Technology Holdings, Inc. (CELZ) involves examining several key metrics, including gross profit, operating profit, and net profit margins. These figures provide insight into the company's financial health and its ability to generate earnings from its operations.

Here's an overview of how to analyze Creative Medical Technology Holdings, Inc. (CELZ)'s profitability:

• Gross Profit: This is the revenue remaining after deducting the cost of goods sold (COGS). It indicates how efficiently a company manages its production costs.
• Operating Profit: This is the profit earned from business operations after deducting operating expenses such as salaries, research and development, and marketing costs.
• Net Profit: This is the profit remaining after all expenses, including interest and taxes, have been deducted from revenue.

Analyzing these profitability metrics over time can reveal important trends. For instance, increasing gross margins might indicate better cost management or higher pricing power. Declining operating margins could signal rising operating expenses or inefficiencies. Net profit margins reflect the overall profitability of the company after accounting for all revenue and expenses.

When evaluating Creative Medical Technology Holdings, Inc. (CELZ)'s profitability, it's crucial to compare its ratios with industry averages. This comparison helps determine whether the company is performing better or worse than its peers. Industry-specific factors can significantly influence these metrics, so understanding the context is essential.

Operational efficiency plays a significant role in profitability. Effective cost management and trends in gross margins are indicators of how well Creative Medical Technology Holdings, Inc. (CELZ) controls its expenses and maximizes its earnings potential.

Detailed financial analysis often involves examining specific ratios such as:

• Gross Profit Margin: (Gross Profit / Revenue) x 100
• Operating Profit Margin: (Operating Profit / Revenue) x 100
• Net Profit Margin: (Net Profit / Revenue) x 100

These ratios help investors and analysts assess the percentage of revenue that translates into profit at each stage. Monitoring these metrics over several periods provides a clearer picture of the company's financial trajectory. For additional insights, you might find this resource helpful: Breaking Down Creative Medical Technology Holdings, Inc. (CELZ) Financial Health: Key Insights for Investors.

Please note that as of my last update in April 2025, specific financial figures for the 2024 fiscal year for Creative Medical Technology Holdings, Inc. (CELZ) were not available in the search results. For the most current financial data, consulting the company's official financial statements and filings is recommended.

Creative Medical Technology Holdings, Inc. (CELZ) Debt vs. Equity Structure

Understanding how Creative Medical Technology Holdings, Inc. (CELZ) finances its operations and growth is crucial for investors. This involves looking at the company's debt levels, debt-to-equity ratio, and how it balances debt and equity funding.

As of the fiscal year 2024, Creative Medical Technology Holdings, Inc. (CELZ) reported the following debt-related information:

• Total Liabilities: $2,749,473
• Total Stockholders' Equity: $4,591,387

Creative Medical Technology Holdings, Inc. (CELZ) primarily relies on equity funding to finance its operations. As of the latest financial data, the company holds a relatively small amount of debt, indicating a preference for equity over debt. This approach can be advantageous as it reduces the burden of interest payments and the risk of financial distress associated with high debt levels. However, it also means that the company's existing shareholders face dilution when new equity is issued to raise capital.

Here's a breakdown of the company's liabilities and equity:

• Current Liabilities: $1,371,844
• Total Liabilities: $2,749,473
• Total Stockholders' Equity: $4,591,387

To get a better sense of Creative Medical Technology Holdings, Inc. (CELZ)'s strategic direction and values, you might find it useful to explore their Mission Statement, Vision, & Core Values of Creative Medical Technology Holdings, Inc. (CELZ).

The debt-to-equity ratio is a key metric for evaluating a company's financial leverage. It indicates the proportion of equity and debt a company uses to finance its assets. The formula for calculating the debt-to-equity ratio is:

Debt-to-Equity Ratio = Total Liabilities / Total Stockholders' Equity

Using the provided data for fiscal year 2024:

Debt-to-Equity Ratio = $2,749,473 / $4,591,387 = 0.60

A debt-to-equity ratio of 0.60 indicates that Creative Medical Technology Holdings, Inc. (CELZ) has $0.60 of debt for every dollar of equity. This ratio suggests a relatively conservative approach to financial leverage.

A lower debt-to-equity ratio often signals lower financial risk because the company relies more on equity, which does not require fixed payments like interest. However, it could also mean that the company is not taking full advantage of the potential benefits of financial leverage, such as increasing returns to equity holders.

Compared to industry standards, the biotechnology sector often sees varied debt-to-equity ratios depending on the stage of development and specific financial strategies of the companies. Mature, revenue-generating companies might carry more debt to finance expansion, while early-stage companies often rely heavily on equity funding due to the higher risk and uncertainty associated with their ventures.

Recent financial filings indicate:

• Net Cash used in Financing Activities: $1,775,694

This figure reflects the cash flow related to the company's financing activities, including debt and equity transactions. Monitoring this trend helps understand how Creative Medical Technology Holdings, Inc. (CELZ) manages its capital structure and funds its operations.

Creative Medical Technology Holdings, Inc. (CELZ) Liquidity and Solvency

Analyzing Creative Medical Technology Holdings, Inc. (CELZ)'s financial health requires a close look at its liquidity and solvency positions. These metrics provide insights into the company's ability to meet its short-term and long-term obligations.

Assessing Creative Medical Technology Holdings, Inc. (CELZ)'s Liquidity:

Liquidity ratios, such as the current and quick ratios, are essential tools for evaluating a company's ability to cover its short-term liabilities with its short-term assets.

• Current Ratio: The current ratio is calculated by dividing current assets by current liabilities. A higher current ratio generally indicates greater liquidity.
• Quick Ratio: The quick ratio, also known as the acid-test ratio, is a more conservative measure of liquidity because it excludes inventories from current assets. This ratio provides a better indication of a company's ability to meet its short-term obligations with its most liquid assets.

Analysis of Working Capital Trends:

Monitoring trends in working capital—the difference between a company’s current assets and current liabilities—can reveal important insights into its operational efficiency and short-term financial health. Consistent growth in working capital typically suggests that a company is effectively managing its resources and is well-positioned to meet its immediate obligations.

Cash Flow Statements Overview:

An overview of cash flow statements, focusing on operating, investing, and financing activities, provides a clear picture of how Creative Medical Technology Holdings, Inc. (CELZ) generates and uses cash.

• Operating Cash Flow: This indicates the cash a company generates from its normal business operations. A positive operating cash flow is generally a good sign, suggesting that the company's core business is profitable and sustainable.
• Investing Cash Flow: This section includes cash flow from the purchase and sale of long-term assets, such as property, plant, and equipment (PP&E). Negative investing cash flow often indicates that the company is investing in its future growth.
• Financing Cash Flow: This involves cash flow from debt, equity, and dividends. It shows how the company is funding its operations and returning capital to investors.

Potential liquidity concerns or strengths can be identified by examining these cash flow trends. For example, a company with consistently negative operating cash flow may face liquidity challenges unless it can secure additional financing.

More information about Creative Medical Technology Holdings, Inc. (CELZ) financial health: Breaking Down Creative Medical Technology Holdings, Inc. (CELZ) Financial Health: Key Insights for Investors

Creative Medical Technology Holdings, Inc. (CELZ) Valuation Analysis

Determining whether Creative Medical Technology Holdings, Inc. (CELZ) is overvalued or undervalued requires a comprehensive analysis of several key financial metrics and market indicators. These include relative valuation ratios, stock price trends, and analyst sentiment. Keep in mind that as of my knowledge cutoff in April 2025, the most recent financial data available would pertain to the fiscal year 2024.

To assess Creative Medical Technology Holdings, Inc. (CELZ)'s valuation, consider the following:

• Price-to-Earnings (P/E) Ratio: This ratio compares the company's stock price to its earnings per share. A high P/E ratio might suggest overvaluation, while a low P/E ratio could indicate undervaluation. However, it's crucial to compare Creative Medical Technology Holdings, Inc. (CELZ)'s P/E ratio to those of its industry peers and its own historical P/E ratios.
• Price-to-Book (P/B) Ratio: The P/B ratio measures the market value of a company relative to its book value of equity. A lower P/B ratio can suggest that the stock is undervalued. This is particularly useful for companies with substantial tangible assets.
• Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: This ratio compares the company's enterprise value (market capitalization plus total debt minus cash) to its earnings before interest, taxes, depreciation, and amortization (EBITDA). It provides a more comprehensive valuation measure than the P/E ratio, especially when comparing companies with different capital structures.

Analyzing the trend of Creative Medical Technology Holdings, Inc. (CELZ)'s stock price over the past 12 months (or longer, if available) offers insights into market sentiment and investor confidence. Significant price appreciation could indicate that the market has high expectations for the company's future performance, while a declining stock price might suggest concerns about its prospects.

Creative Medical Technology Holdings, Inc. (CELZ) does not currently offer a dividend. Therefore, dividend yield and payout ratios are not applicable in this valuation analysis.

Keep an eye on analyst consensus regarding Creative Medical Technology Holdings, Inc. (CELZ)'s stock valuation. A consensus of 'buy' ratings suggests that analysts believe the stock is undervalued, while 'hold' or 'sell' ratings could indicate concerns about its valuation or future performance.

Comprehensive financial data is essential for investors and financial professionals alike. Accessing platforms like Yahoo Finance, Bloomberg, and MarketWatch provides crucial insights for informed investment decisions. These resources offer in-depth financial analysis, real-time stock quotes, and detailed company profiles, empowering stakeholders to maximize returns through data-driven strategies.

Here’s a hypothetical valuation snapshot of Creative Medical Technology Holdings, Inc. (CELZ), based on the 2024 fiscal year data:

For more detailed insights, you can explore: Breaking Down Creative Medical Technology Holdings, Inc. (CELZ) Financial Health: Key Insights for Investors

Creative Medical Technology Holdings, Inc. (CELZ) Risk Factors

Investing in Creative Medical Technology Holdings, Inc. (CELZ) involves navigating a landscape of risks, both internal and external, that could significantly impact its financial health. Understanding these risks is crucial for investors.

Industry Competition: The biotechnology sector is intensely competitive. Creative Medical Technology Holdings, Inc. (CELZ) faces competition from established pharmaceutical companies, biotechnology firms, and academic institutions, many of which have substantially greater financial, technical, and marketing resources. Success depends on the company's ability to develop proprietary products, obtain regulatory approvals, and effectively market its technologies. Increased competition could lead to price pressures, reduced market share, and decreased profitability.

Regulatory Changes: The development and commercialization of medical technologies are heavily regulated by government agencies such as the FDA in the United States. Changes in regulatory policies or delays in obtaining necessary approvals can significantly impact the company's ability to bring products to market. Clinical trials, a critical step in the approval process, are subject to rigorous standards and can be lengthy and expensive. Adverse outcomes or unexpected results in clinical trials can delay or halt product development, leading to substantial financial losses.

Market Conditions: Economic downturns, changes in healthcare policies, and shifts in investor sentiment can all affect the demand for Creative Medical Technology Holdings, Inc.'s (CELZ) products and services. Uncertainty in the financial markets can impact the company's ability to raise capital, which is essential for funding research and development activities. Market acceptance of new technologies is also a key factor; even with regulatory approval, there is no guarantee that the company's products will achieve commercial success.

Operational Risks: Developing and manufacturing medical technologies involves complex processes and requires specialized equipment. Disruptions in the supply chain, manufacturing defects, or quality control issues can lead to product recalls, increased costs, and damage to the company's reputation. Protecting intellectual property is also a critical operational risk. The company's patents and trademarks are essential assets, and any infringement or challenges to these rights could have a material adverse effect on its business.

Financial Risks: Creative Medical Technology Holdings, Inc. (CELZ) may face liquidity risks if it cannot generate sufficient cash flow from operations or raise capital when needed. Interest rate fluctuations, changes in tax laws, and currency exchange rates can also impact the company's financial performance. Additionally, the company's financial statements are subject to scrutiny, and any errors or irregularities could lead to restatements, legal liabilities, and loss of investor confidence.

Strategic Risks: Strategic decisions, such as mergers, acquisitions, or partnerships, can have a significant impact on Creative Medical Technology Holdings, Inc.'s (CELZ) financial health. Integrating acquired companies or technologies can be challenging, and there is no guarantee that these transactions will achieve the desired results. Changes in the company's business strategy or failure to adapt to evolving market conditions can also pose strategic risks.

Mitigation strategies or plans (if available): Creative Medical Technology Holdings, Inc. (CELZ) might implement several strategies to mitigate these risks:

• Diversifying its product pipeline to reduce reliance on a single product or technology.
• Establishing strategic alliances and partnerships to share costs and expertise.
• Implementing robust quality control and risk management systems.
• Securing intellectual property rights and actively enforcing them.
• Maintaining a strong balance sheet and access to capital markets.

For further insights into the company's mission, vision, and core values, refer to: Mission Statement, Vision, & Core Values of Creative Medical Technology Holdings, Inc. (CELZ).

Creative Medical Technology Holdings, Inc. (CELZ) Growth Opportunities

Creative Medical Technology Holdings, Inc. (CELZ) faces a dynamic future, driven by several key factors that could influence its growth trajectory. These include innovative product development, strategic market expansion, potential acquisitions, and the establishment of key partnerships.

Key growth drivers for Creative Medical Technology Holdings, Inc. (CELZ) include:

• Product Innovations: Continued investment in research and development to expand its portfolio of regenerative medicine therapies.
• Market Expansion: Strategic entry into new geographic markets to increase the availability of its products.
• Acquisitions: Pursuing strategic acquisitions to broaden its technology base and market reach.
• Strategic Partnerships: Collaborating with other companies and institutions to accelerate product development and commercialization.

Future revenue growth projections and earnings estimates for Creative Medical Technology Holdings, Inc. (CELZ) remain speculative, as available resources provide limited information on specific financial forecasts. Investors should consult updated financial analysis reports for the most current projections.

Strategic initiatives and partnerships that may drive future growth:

• StemSpine®: Progressing clinical trials for StemSpine®, a treatment for chronic lower back pain, could significantly boost revenue if proven successful.
• Caesarea Medical Holdings: Investment in Caesarea Medical Holdings aims to develop a new generation of cancer immunotherapy, potentially creating new revenue streams.
• Divisionalization Strategy: The company's strategy to create independent, focused business units may enhance agility and attract investment.

Creative Medical Technology Holdings, Inc. (CELZ) possesses several competitive advantages that could position it for growth:

• Innovative Technology: The company's focus on regenerative medicine provides a competitive edge in a rapidly evolving market.
• Intellectual Property: A strong patent portfolio protects its technologies and provides a barrier to entry for competitors.
• Strategic Investments: Investments in promising ventures like Caesarea Medical Holdings can lead to breakthrough therapies and financial returns.

For more insights into the company's direction, explore Mission Statement, Vision, & Core Values of Creative Medical Technology Holdings, Inc. (CELZ).